Anavex Life Sciences Corp (OTCMKTS:AVXL), a Biopharma company formulating drug candidates to cure Alzheimer, other CNS diseases, and cancer, informed the appointment of Jacqueline French, MD, to its Scientific Advisory Board. He is a renowned expert on epilepsy, clinical trial methodology and new therapeutic interventions.
The management speaks
Christopher U. Missling, the President and CEO of Anavex stated that the management is excited to welcome French as a Scientific Advisor. Her unmatched work has resulted in epilepsy treatments. She is known for leading the clinical care of seizures. Her expertise as well as her extensive experience and expertise in neurology, will add value as the company moves forward with development of ANAVEX 2-73.
Dr. French plays a vital role in the segment of development of novel therapeutics for epilepsy. She co-authored various AAN clinical practice guidelines at the American Academy of Neurology. She also looks after a bi-annual symposium on trial design and is a member of the American Academy of Neurology. In addition, she has written several research articles, chapters and editorials. Her articles have been published in renowned publications. She even edited two key books on epilepsy. The skills do not end at writing as she is a famous global speaker on antiepileptic drug treatments and related topics.
Expressing her views on the new role with Anavex Dr. French said that she is extremely delighted with the positive data for ANAVEX 2-73, which indicates a considerable reduction in anti-seizure efficacy. Additionally, drug reflected safety features in Phase 1 human trial. The data is important to support next-general epilepsy therapies. She further added that she will work in association with Anavex and its team of scientific advisors to develop ANAVEX 2-73. Recently, she served as President of the renowned American Epilepsy Society. She worked with the US FDA to develop novel trial designs.